Skip to main content

Investor Relations

We aim at sustaining a continuous, clear and trustful communication with all our partners and stakeholders.

Integrated diagnostic solutions for critical care settings

We are committed to improving patient outcomes with innovative diagnostic solutions for acute care that allow the diagnosis, outcome prediction, and monitoring of patients with acute medical conditions.

SphingoTec develops and markets innovative in vitro diagnostics solutions for novel and proprietary blood-based protein biomarkers. Our aspiration is to effectively translate scientific advancements to routine clinical practice. We develop biomarkers addressing diagnostically underserved critical care conditions such sepsis, acute heart failure, acute kidney injury, and cardiogenic shock.

SphingoTec is a privately held company with the headquarter in Hennigsdorf near Berlin and with a wholly owned subsidiary in San Diego, USA. We have a long history of biomarker discovery, development and validation at our German location. Our U.S. location is home to the production of our fully developed Point of Care testing platform Nexus IB10.


Our investors share our vision of improving patient outcomes

SphingoTec in a nutshell

Our portfolio of tests supports a better management of critically ill patients, where fast and reliable information is essential in taking treatment decisions. We are a fully integrated diagnostics company: our innovative biomarkers are commercially available on the point of care platform Nexus IB10.

The assay portfolio for near patient testing goes beyond innovation: on the Nexus IB10 platform, clinicians can deploy a wide range of commonly used parameters in acute and critical care settings, making the analyzer a useful addition to intensive care units (ICU), emergency departments (ED), and other near patient settings.

Investment Thesis


A unique platform

A rapid point-of-care platform that is a bed-side solution to diagnostic healthcare challenges.

Early stage opportunity

An opportunity of investment in more than 200 patents that could benefit over 60 million patients worldwide.

Skillful team

A skilled international team with a broad scope of experience committed to improve patient lives

An innovative portfolio

Innovative biomarkers for diagnosis, prediction and monitoring of ICU mortality drivers.

Latest News

15. November 2022
Boditech Med Inc. and SphingoTec GmbH have entered into a non-exclusive royalty-bearing license agreement. Under the terms of this agreement, Boditech has obtained the rights to develop and commercialize clinical tests for the kidney function biomarker penKid on its renowned AFIAS and ichroma Point of Care platforms.
Read more
26. August 2022
Four units at the University Hospital Heidelberg and Heidelberg Kidney Center implement Proenkephalin (penKid) in a pilot biomarker-based treatment approach to diagnose AKI faster and monitor it more accurately across departments.
Read more
08. August 2022
International medical experts discussed the latest developments in diagnostic and therapeutic innovations for advancing precision medicine in critically ill patients during the 4th Scientific Symposium.
Read more

Events & Expos

29. March - 01. April 2023

09:33 - 11:34

San Diego, USA

The CRRT conference provides a comprehensive review of advances in clinical care, research, and technology in critical care medicine with a focus on the kidney and renal support techniques. We are…

Read more
21. - 24. March 2023

08:05 - 10:07

Brussels, Belgium

The International Symposium on Intensive Care and Emergency Medicine is organized by the Departments of Intensive Care and Emergency Medicine of Erasme University Hospital, Université Libre de…

Read more
15. - 17. February 2023

08:02 - 10:03

Bremen, Germany

The Symposium Intensivmedizin + Intensivpflege in Bremen is the largest annual meeting of intensive care physicians and nurses, administrative experts, and industry representatives independent of…

Read more

Contact Investor Relations

Do you have any questions or require more information? Please contact the Investor Relations Team, send us an e-mail or call us.

phone: + 49 (0)330 220 56 5 - 0

Dr. Angelo Moesslang

Chief Financial Officer and Managing Director

Subscribe to our Newsletter

Follow the link below to subscribe to our Newsletter & receive updates on our company and products

Subscribe now